Barclays
HRTX icon

Barclays’s Heron Therapeutics HRTX Stock Holding History

Barclays’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-1,300
Closed -$31K – 6272
2019
Q4 		$31K Buy
1,300
+1,100
+550% +$24.3K ﹤0.01% 5881
2019
Q3 		$4K Buy
+200
New +$3.68K ﹤0.01% 6479
2019
Q1 		– Sell
-9,300
Closed -$241K – 7141
2018
Q4 		$241K Sell
9,300
-39,200
-81% -$1.08M ﹤0.01% 4448
2018
Q3 		$1.53M Buy
48,500
+43,400
+851% +$1.62M ﹤0.01% 3194
2018
Q2 		$198K Buy
5,100
+4,500
+750% +$143K ﹤0.01% 4732
2018
Q1 		$17K Sell
600
-2,800
-82% -$63.5K ﹤0.01% 6488
2017
Q4 		$62K Buy
3,400
+1,900
+127% +$31K ﹤0.01% 5613
2017
Q3 		$24K Buy
1,500
+500
+50% +$7.84K ﹤0.01% 5719
2017
Q2 		$14K Hold
1,000
– – ﹤0.01% 5935
2017
Q1 		$15K Buy
+1,000
New +$13.8K ﹤0.01% 5924
2015
Q3 		– Sell
-180,000
Closed -$5.58M – 6922
2015
Q2 		$5.58M Buy
+180,000
New +$3.39M 0.01% 1404

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

Barclays's HRTX Position: Q1 2026 in Review

Barclays reduced its Heron Therapeutics (HRTX) stake by 70% in Q1 2026, selling an estimated $245K and leaving 91,394 shares worth $73.1K. The position accounts for ﹤0.01% of the portfolio, ranked #4162.

Barclays first reported a position in HRTX in Q2 2014 and has held it in 48 quarters since. The position peaked at $2.25M in Q1 2021. 167 funds tracked by Wall St. Rank hold HRTX as of Q1 2026.

  • Barclays held 91,394 shares of Heron Therapeutics worth $73.1K as of Q1 2026.
  • Barclays sold 211,815 Heron Therapeutics shares in Q1 2026, an estimated $245K.
  • Heron Therapeutics made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #4162 holding.
  • Barclays first reported a position in Heron Therapeutics in Q2 2014 and has held it in 48 quarters since.
  • Barclays's Heron Therapeutics position peaked at $2.25M in Q1 2021.
  • 167 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.